Details for Patent: 9,278,995
✉ Email this page to a colleague
Which drugs does patent 9,278,995 protect, and when does it expire?
Patent 9,278,995 protects PARSABIV and is included in one NDA.
This patent has fifty-six patent family members in thirty countries.
Summary for Patent: 9,278,995
| Title: | Therapeutic agents for reducing parathyroid hormone levels |
| Abstract: | Compounds having activity for lowering parathyroid hormone levels are described. In one embodiment, the compounds are comprised of a contiguous sequence of subunits, X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7, wherein the X.sub.1 subunit comprises a thiol-containing moiety and the distribution of charge on the X.sub.2-X.sub.7 subunits provides the desired activity. Methods of using the compounds for treating hyperparathyroidism, bone disease and/or hypercalcemic disorders are also described, and in particular, methods for lowering plasma PTH and serum calcium are provided. The compounds can be used to treat subjects having, for example: primary, secondary or tertiary hyperparathyroidism; hypercalcemia of malignancy; metastatic bone disease; or osteoporosis. |
| Inventor(s): | Karim; Felix (Walnut Creek, CA), Baruch; Amos (San Francisco, CA), Maclean; Derek (Los Altos, CA), Das; Kanad (San Francisco, CA), Yin; Qun (Palo Alto, CA) |
| Assignee: | KAI PHARMACEUTICALS, INC. (South San Francisco, CA) |
| Application Number: | 13/769,744 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,278,995 |
|
Patent Claim Types: see list of patent claims | Compound; |
More… ↓ |
Drugs Protected by US Patent 9,278,995
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-001 | Feb 7, 2017 | RX | Yes | Yes | 9,278,995 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-002 | Feb 7, 2017 | RX | Yes | Yes | 9,278,995 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Kai Pharms Inc | PARSABIV | etelcalcetide | SOLUTION;INTRAVENOUS | 208325-003 | Feb 7, 2017 | RX | Yes | Yes | 9,278,995 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,278,995
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2459208 | ⤷ Subscribe | PA2017007 | Lithuania | ⤷ Subscribe |
| European Patent Office | 2459208 | ⤷ Subscribe | 300864 | Netherlands | ⤷ Subscribe |
| European Patent Office | 2459208 | ⤷ Subscribe | 122017000021 | Germany | ⤷ Subscribe |
| European Patent Office | 2459208 | ⤷ Subscribe | C20170006 00208 | Estonia | ⤷ Subscribe |
| European Patent Office | 2459208 | ⤷ Subscribe | CA 2017 00006 | Denmark | ⤷ Subscribe |
| European Patent Office | 2459208 | ⤷ Subscribe | 8/2017 | Austria | ⤷ Subscribe |
| European Patent Office | 2459208 | ⤷ Subscribe | LUC00008 | Luxembourg | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
